Recent Updates
Recently added Catalysts
KRMD Positive Sentiment Score: 70/100

KORU Medical Systems to Report First Quarter 2026 Financial Results on May 6, 2026

Friday, April 17, 2026 2 min read
Key Takeaway: KORU Medical Systems, Inc. will report its first quarter 2026 financial results on May 6, 2026. A conference call and webcast will be held at 4:30 p.m. ET to discuss these results and provide a corporate update. The company specializes in large volume subcutaneous infusion solutions aimed at improving patient quality of life.

Market Sentiment Analysis

POSITIVE FACTORS

  • KORU Medical is set to report financial results, indicating ongoing business activity.
  • The company is focused on innovative patient-centric solutions, enhancing patient care.
  • Management will provide a corporate update, showing transparency and engagement with investors.

Full Press Release Details

MAHWAH, NJ--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”),a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2026 financial results on Wednesday, May 6, 2026. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
Conference Call and Webcast Details
The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international callers. A live and archived webcast of the event can be accessed via the IR Calendar on theNews/Eventspage of the Investors section of KORU Medical’s website atwww.korumedical.com. The archived webcast will be available for six months.
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60®and FreedomEdge®Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Service and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visitwww.korumedical.com.
Investor Contact:Louisa Smithinvestor@korumedical.com

Frequently Asked Questions

When will KORU Medical report its Q1 2026 financial results?

KORU Medical will report its Q1 2026 financial results on May 6, 2026.

What time is the KORU Medical conference call?

The conference call is scheduled for 4:30 p.m. ET on May 6, 2026.

How can I access the KORU Medical conference call?

The conference call can be accessed by dialing (877)-407-0784 for U.S. participants.

What products does KORU Medical specialize in?

KORU Medical specializes in large volume subcutaneous infusion solutions.

Tags: KRMD Viatris Investor Conferences Healthcare KORU Medical financial results conference call infusion solutions
Last updated: Apr 17, 2026